IPCALABNSEIPCA Laboratories Limited· PharmaceuticalsMediumNeutral
Announced Fri, 10 Apr · 17:19 IST

Kaygee Investments Private Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Ownership Changes View source PDF

IPCALAB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+1.2%1-day move
₹1455.50
prior close
₹1436.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.9+1.1+0.7+1.0+1.2+0.9+1.2+1.0+1.9+4.9+8.2+3.1+8.0+25.4
Up moveDown movePending
AI summary

Kaygee Investments Private Limited, acting as promoter of IPCA Laboratories along with other promoter entities (Chandurkar Investments, Kaygee Laboratories, Makers Laboratories, and related individuals including the Chandurkar and Godha families), has submitted a declaration to NSE and BSE under Regulation 31(4) of SEBI's Takeover Regulations. The disclosure confirms that the promoters have NOT made any encumbrance, directly or indirectly, on their equity shares in IPCA Laboratories during the financial year ended 31st March 2026. This is a negative declaration (no encumbrance) filed as part of routine regulatory compliance. The filing includes a list of 15 promoter entities and persons acting in concert (PACs).

Likely market impact

This is a positive compliance disclosure confirming promoters have not pledged their shares, eliminating concerns about potential margin call risks or forced selling from share encumbrances. This is neutral for stock price as it simply confirms status quo regarding promoter share holdings.